Evolution and predictive factors of thyroid disorder due to interferon alpha in the treatment of hepatitis C

Table 1 Characteristics of the study population

Characteristics	Total group (n = 301)
Age1 (yr)	48.27 ± 11.79
Gender (%, M/F)	57.5/42.5
Contamination mode (%)
Tranfusion	27.2
Drug-addict	26.9
Blood exposure accident	7.6
Others	38.2
Genotype (% with 1/2/3/4/5/ND)	35/11/18/8/2/26
Stage of fibrosis (% with stage 0/1/2/3/4/ND)	1/11/42/20/20/6
Type of treatment (%)
With IFNα	3.3
Peg-interferon	9.0
IFNα + ribavirin	27.2
Peg-interferon + ribavirin	60.4
Duration of treatment (mo)1	7.91 ± 3.78
TSH before treatment (MIU/L)1	1.54 ± 1.25
Positive antibodies before treatment
TPOAb	12/229
TGAb	8/227
TSHRAb	1/95

ND: Not determined.

¹mean ± SD.

Table 2 Classification of thyroid disorder and long-term normalisation of dysthyroidism (n = 30)

	Type of dysthyroidism of normalisation	Discontinued treatment	Normalisation	Mean delay (mo)
Hyperthyroidism	13	9	9	7.44 ± 7.051
Silent thyroiditis	5	4	5	6.80 ± 3.701
Graves’ disease	4	2	1	5
NC	2	2	2	2.00 ± 1.411
Triphasic evolution	2	1	1	24
Hypothyroidism	11	6	3	10.67 ± 4.041
Autoimmune	10	5	2	8.50 ± 2.121
NC	1	1	1	15
Biphasic evolution	6	3	4	10.75 ± 5.501

NC: Not classified.

¹mean ± SD.

Table 3 Features associated with dysthyroidism

	With dysthyroidism	Without dysthyroidism	P
Age1 (yr)	46.20 ± 10.08	48.49 ± 11.96	0.40
Female (%)	56.9	40.9	0.05
Contamination mode (%)
Transfusion	33.3	26.6
Drug-addict	20.0	27.7
Blood exposure accident	13.3	7.0
Others	33.3	38.7
Genotype (%, 1/2/3/4/5/6/ND)	57/13/13/0/0/0/17	33/11/20/9/1/0/26	0.20
Stage of fibrosis < F2 (%)	30.0	10.3	0.009
Type of treatment (%)
IFNα	3.3	3.3
Peg-interferon	6.7	9.3
IFNα + ribavirin	16.7	28.5
Peg-interferon + ribavirin	73.3	58.9
Duration of treatment1 (mo )	7.73 ± 3.64	8.09 ± 3.93	0.30
Positive antibodies before treatment (%)
TPOAb	26.9	2.5	< 0.0003
TgAb	18.5	1.5	0.0003
TSHRAb	0.0	1.3	0.42

ND: Not determined.

¹mean ± SD.